ホーム>>Seltorexant hydrochloride

Seltorexant hydrochloride (Synonyms: JNJ-42847922 hydrochloride)

カタログ番号GC61273

セルトレキサント塩酸塩 (JNJ-42847922 塩酸塩) は、経口活性、高親和性、選択的 OX2R アンタゴニスト (ヒトおよびラット OX2R の pKi 値 8.0 および 8.1) です。

Products are for research use only. Not for human use. We do not sell to patients.

Seltorexant hydrochloride 化学構造

Cas No.: 1293284-49-7

サイズ 価格 在庫数 個数
5mg
$102.00
在庫あり
10mg
$153.00
在庫あり
50mg
$422.00
在庫あり
100mg
$667.00
在庫あり
250mg
$1,344.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Seltorexant hydrochloride (JNJ-42847922 hydrochloride) is an orally active, high-affinity, and selective OX2R antagonist (pKi values of 8.0 and 8.1 for human and rat OX2R). Seltorexant hydrochloride crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain[1].

Seltorexant hydrochloride (JNJ-42847922 hydrochloride) (3-30 mg/kg; p.o.) dose-dependently induces and prolongs sleep in male Sprague-Dawley rats[1].The sleep-promoting effects of Seltorexant hydrochloride (30 mg/kg; p.o.; per day for 7 days) are maintained upon 7-day repeated dosing in rats[1]. Animal Model: Male Sprague-Dawley rats (350-450 g)[1]

[1]. Bonaventure P, et al. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther. 2015 Sep;354(3):471-82.

レビュー

Review for Seltorexant hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Seltorexant hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.